Friday 24 May 2019

Malin-backed Kymab preps IPO

Photo: Stock Image
Photo: Stock Image
Donal O'Donovan

Donal O'Donovan

Kymab Group, a UK-based developer of a treatment for eczema, has kicked off a US stock market flotation in a move that is set to return cash to Irish backer Malin.

Last year - following a poor stock market performance and amid senior management changes - Malin undertook a strategic review.

Please log in or register with Independent.ie for free access to this article.

Log In

As part of that it opted to focus on four core assets, including Kymab - where it owns an 8pc stake.

Last month, another of Malin's priority investments - Poseida, which is developing a treatment for bone marrow cancer - shelved plans for a flotation. It is now tipped to be sold.

Yesterday, Kymab said it had previously confidentially submitted a draft registration statement to the US Securities and Exchange Commission for a proposed initial public offering (IPO).

Malin shares closed down 3.7pc yesterday, at €5.20 each.

Irish Independent

Also in Business